Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a Canadian research and product development company focused on advanced vision correction, announced on July 31, 2026, the completion of the second tranche of its unit private placement. The company issued 6,250,000 units at a price of $0.40 per unit, generating gross proceeds of $2.5 million. Each unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to purchase an additional common share at an exercise price of $0.50 for a period of three years from issuance.
To date, the company has raised an aggregate of $2,948,130 under the offering, which was initially announced on July 7, July 29, and July 30, 2026. The total offering is for up to 8,000,000 units, with a goal of raising up to $3.2 million. The company intends to close the remainder of the offering in one or more subsequent tranches.
As part of the offering, Ocumetics paid cash commissions of $200,000 and issued 500,000 warrants to Ventum Financial Corp. for its assistance in finding subscribers. The warrants are subject to an acceleration clause: if the volume-weighted average trading price of the common shares on the TSX Venture Exchange is at least $0.75 for 30 consecutive trading days, the company may accelerate the expiry date of the warrants to a date not less than 30 days after notice is provided.
The net proceeds from the offering are expected to be used to fund the company's continuing first-in-human clinical trials, ongoing research and development, and general working capital. However, the actual allocation may vary depending on future operations, events, or opportunities.
Ocumetics is developing a dynamic intraocular lens designed to fit within the natural lens compartment of the eye. The lens aims to allow the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses and providing clear vision at all distances without perceptible time lag. The company is currently in the first-in-human early feasibility study phase of this technology, which could transform the ophthalmic industry by offering an alternative to glasses and contact lenses.
The completion of this financing is a critical step for Ocumetics as it advances its clinical trials and moves closer to bringing this innovative technology to market. For leaders in the business and technology sectors, this development highlights the ongoing innovation in medical technology and the potential for significant disruption in the vision correction market. The successful fundraising also demonstrates investor confidence in Ocumetics' approach and its potential to address a common global need.
The common shares and warrants issued in this tranche are subject to a hold period of four months and one day from the date of issuance, with finder warrants being non-transferable. The offering remains subject to final approval from the TSX Venture Exchange, though conditional approval has already been obtained.
Ocumetics' progress is noteworthy as it navigates the complex regulatory and clinical pathways required to bring a novel medical device to market. The company's focus on enhancing quality of life through advanced vision correction solutions aligns with broader trends in personalized medicine and patient-centric care. As the company continues to secure funding and advance its clinical trials, its success could have far-reaching implications for patients, healthcare providers, and the medical technology industry.
